Loading clinical trials...

COMPLETEDPHASE2

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for Therapy-Related Myelodysplastic Syndrome/Therapy -Related Acute Myeloid Leukemia

NCT00774046•University of Chicago

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the effectiveness of a particular combination of drugs used to treat cancer.

Eligibility

Age

10 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients must have received cytotoxic chemotherapy,radiation,or a drug known to affect the properties of DNA or cell growth for some condition other than acute myeloid leukemia prior to diagnosis.
•Patients must have t-MDS/t-AML
•To be eligible for allogeneic transplantation, patients must have a suitable donor who is HLA compatible.
•Patients must be over the age of 10.
•Patients must be reviewed and discussed at the Leukemia and Transplant Conferences of the Section of Hematology/Oncology.

Exclusion Criteria

•Patients must not have any other serious medical condition(e.g.uncontrolled or severe cardiovascular disease, diabetes, pulmonary disease, or infection)
•Psychiatric condition which would prevent compliance or possibly be worsened by treatment

Locations (1)

The University of Chicago

Chicago, Illinois, United States

Key Dates

Start Date

December 1, 2002

Primary Completion Date

March 1, 2011

Completion Date

March 1, 2011

Last Updated

February 11, 2014

Enrollment

ACTUAL participants

Conditions

Myelodysplastic SyndromeAcute Myeloid Leukemia

Interventions

Ara-C

DRUG

Mitoxantrone

DRUG

Etoposide

DRUG

Phase I Study of HC-7366 for Acute Myeloid Leukemia

NCT06285890

Acute Myeloid Leukemia

View study

RECRUITINGPHASE2

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

NCT06220162

Acute Myeloid Leukemia

View study

RECRUITINGPHASE2

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 11, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

Inclusion Criteria

Exclusion Criteria

Phase I Study of HC-7366 for Acute Myeloid Leukemia

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias